Quadrant Biosciences CEO Rich Uhlig named Top 50 Healthcare Technology CEO

Go Back

SYRACUSE, NY April 15, 2021 - Quadrant Biosciences Inc., a leading developer of novel molecular diagnostic tools, announced that CEO Richard Uhlig has been recognized as one of the Top 50 Healthcare Technology CEOs of 2021 by The Healthcare Technology Report. Uhlig was recognized for his exceptional leadership and guidance in the midst of the global pandemic, which included the development of a highly sensitive q-PCR saliva test for COVID-19.

According to the Health Technology Report, “the award recognizes some of the most accomplished executives in healthcare technology whose leadership has been critical in developing industry leading medical devices, next generation software platforms, and advanced diagnostics, and recognizing unique opportunities for transformation and growth within their areas of expertise.”

Quadrant, in partnership with SUNY Upstate Medical University, developed the Clarifi COVID-19 saliva test kit in 2020 in response to the demand for highly sensitive, saliva based COVID-19 tests. The Clarifi COVID-19 Test Kit, which received FDA emergency use authorization in September 2020, is currently ranked as the most sensitive saliva test on the market by the FDA, and has been administered well over a million times. The company has also developed Clarifi ASD®, a novel molecular saliva test for autism spectrum disorder. Research and development of molecular diagnostics tests for mild traumatic brain injury and Parkinson's disease are underway.

Read more here.

Post Date

Apr 19th 2021